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REPLY: Complete Revascularization inPatients Undergoing Primary Percutaneous
Coronary Intervention for STEMI
Is It Really What We Should Be Doing?We read with interest the letter from Dr. Dastidar and
colleagues in which they express their views and
compare our report of the randomized CvLPRIT
(Complete Versus Lesion-Only Primary PCI Trial) (1)
with their in-house clinical experience.
They suggest that the trial was not run according to
current European Society of Cardiology guidelines. In
fact, it remains unclear how best to manage multi-
vessel disease ST-segment elevation myocardial
infarction patients and in the last iteration of the Eu-
ropean Society of Cardiology ST-segment elevation
myocardial infarction guidelines this was listed as a
“Gap in the Knowledge.” Furthermore, the strategy
suggested by Dr. Dastidar and colleagues (of routine
noninvasive testing) is not within the guidelines,
although the control group in CvLPRIT could undergo
intervention on the non-infarct-related artery if there
were reliable symptoms and evidence of ischemia on
subsequent noninvasive testing. Importantly, the
meta-analysis they quote (Vlaar et al. [2]) was pub-
lished before the 2 most signiﬁcant randomized
controlled trials (PRAMI [Preventive Angioplasty
in AcuteMyocardial Infarction] and CvLPRIT), so itwas
unlikely to have found overall beneﬁt for intervention.
In CvLPRIT, as a safety measure, all patients had a
“nested” myocardial perfusion scan at 6 weeks, with
the intention that information on any patient with
>20% left ventricular ischemic burden be sent to
the responsible physician (A. Keilon, unpublished
data, June 2015). In essence, no patients needed to beso reported, which brings the debate to the issue of the
value of ischemia testing in such patients.Whether it is
the stability of the lesion rather than the presence of
signiﬁcant physiological ﬂow reduction that leads
to non-infarct-related artery lesion-driven adverse
outcomes remains undetermined. Indeed, there is no
evidence in the primary percutaneous coronary inter-
vention era to support the use of ischemia testing to
guide management. Furthermore, both CvLPRIT and
PRAMI have shown a beneﬁt of in-hospital complete
revascularization with early separation of the survival
curves, which suggests that beneﬁts may accrue from
mechanisms other than ischemia reduction.
CvLPRIT was consistent with PRAMI in demon-
strating signiﬁcant beneﬁt from total revasculariza-
tion. However, as has been stated in our paper (1), and
during presentations, we never purported to have the
whole answer.What these 2 trials have done is raise the
issue of how best to manage such patients. They were
insufﬁciently powered for death and myocardial
infarction, and larger trials are needed and planned,
including one by the CvLPRIT and PRAMI investi-
gators, which will be powered for death and myocar-
dial infarction and will assess the value of fractional
ﬂow reserve in the non-infarct-related artery.
In the meantime, physicians must make their own
judgment and, if faced with an angiographically
signiﬁcant lesion in the proximal portion of the right
coronary artery in a patient presenting with a left
anterior descending ST-segment elevation myocar-
dial infarction, decide, based on the current ran-
domized data (see meta-analysis by El-Hayek et al.
[3]) whether it is in the patient’s best interest to
choose to leave this non-infarct-related artery lesion
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